Scarica l'app Stockscreener
48.47
1.85%
0.88
Dopo l'orario di chiusura:
48.85
0.38
+0.78%
Precedente Chiudi:
$47.59
Aprire:
$47.39
Volume 24 ore:
1.50M
Relative Volume:
0.62
Capitalizzazione di mercato:
$6.24B
Reddito:
$10.12M
Utile/perdita netta:
$-280.49M
Rapporto P/E:
-16.77
EPS:
-2.89
Flusso di cassa netto:
$-188.51M
1 W Prestazione:
-0.23%
1M Prestazione:
+29.81%
6M Prestazione:
+69.71%
1 anno Prestazione:
+16.21%
Intervallo 1D:
$47.00
$48.69
Intervallo di 1 settimana:
$45.24
$49.11
Portata 52W:
$21.51
$56.00
Avidity Biosciences Inc Stock (RNA) Company Profile
Nome
Avidity Biosciences Inc
Settore
Industria
Telefono
858-401-7900
Indirizzo
10578 SCIENCE CENTER DRIVE, SAN DIEGO, CA
Confronta RNA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RNA
Avidity Biosciences Inc
|
48.47 | 6.08B | 10.12M | -280.49M | -188.51M | -2.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.93 | 102.81B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.54 | 58.59B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.22 | 61.25B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
733.66 | 43.23B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
318.73 | 36.53B | 3.81B | -644.79M | -669.77M | -6.24 |
Avidity Biosciences Inc Stock (RNA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-10 | Ripresa | Goldman | Buy |
| 2025-06-24 | Iniziato | Bernstein | Outperform |
| 2025-06-17 | Iniziato | Wolfe Research | Outperform |
| 2025-06-11 | Iniziato | Raymond James | Strong Buy |
| 2025-03-13 | Iniziato | Citigroup | Buy |
| 2025-03-12 | Iniziato | BMO Capital Markets | Outperform |
| 2025-03-07 | Iniziato | Scotiabank | Sector Outperform |
| 2024-12-20 | Iniziato | H.C. Wainwright | Buy |
| 2024-11-26 | Iniziato | RBC Capital Mkts | Outperform |
| 2024-09-24 | Iniziato | Goldman | Buy |
| 2024-08-28 | Iniziato | Barclays | Overweight |
| 2024-05-03 | Iniziato | BofA Securities | Buy |
| 2024-03-14 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-05-22 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2023-03-31 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-07-20 | Iniziato | Chardan Capital Markets | Buy |
| 2022-07-12 | Iniziato | Raymond James | Strong Buy |
| 2021-09-07 | Iniziato | Evercore ISI | Outperform |
| 2021-06-17 | Iniziato | Needham | Buy |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2020-07-07 | Iniziato | Cowen | Outperform |
| 2020-07-07 | Iniziato | Credit Suisse | Outperform |
| 2020-07-07 | Iniziato | SVB Leerink | Outperform |
| 2020-07-07 | Iniziato | Wells Fargo | Overweight |
Mostra tutto
Avidity Biosciences Inc Borsa (RNA) Ultime notizie
Avidity Biosciences Inc. stock momentum explainedWeekly Profit Analysis & Technical Confirmation Alerts - Newser
Volume spikes in Avidity Biosciences Inc. stock – what they meanPortfolio Return Summary & Verified Momentum Stock Watchlist - Newser
Is Avidity Biosciences Inc. forming a reversal patternQuarterly Performance Summary & Accurate Trade Setup Notifications - Newser
Is now a turning point for Avidity Biosciences Inc.Trade Exit Summary & Real-Time Buy Zone Alerts - Newser
Is Avidity Biosciences Inc. stock ready for a breakout2025 Stock Rankings & Free Real-Time Volume Trigger Notifications - Newser
News impact scoring models applied to Avidity Biosciences Inc.Analyst Downgrade & Risk Controlled Daily Plans - Newser
Price momentum metrics for Avidity Biosciences Inc. explainedJuly 2025 Update & Weekly Stock Breakout Alerts - Newser
Full technical analysis of Avidity Biosciences Inc. stock2025 Market Sentiment & Weekly Watchlist for Hot Stocks - Newser
Technical analysis overview for Avidity Biosciences Inc. stockWeekly Investment Summary & Low Risk High Reward Trade Ideas - Newser
Order flow analysis tools used on Avidity Biosciences Inc.July 2025 Setups & High Conviction Investment Ideas - Newser
Avidity Biosciences CPO sells $8914 in RNA stock - Investing.com
Avidity Biosciences' Kathleen Gallagher Sells 188 Shares at $47.42 - AInvest
Arrowhead, Novartis in up to $2 billion deal for neuromuscular therapy license - Reuters
Is Avidity Biosciences Inc. stock showing strong momentumJuly 2025 Outlook & Capital Efficiency Focused Strategies - khodrobank.com
Reversal indicators forming on Avidity Biosciences Inc. stockEarnings Beat & Free Weekly Watchlist of Top Performers - Newser
Detecting price anomalies in Avidity Biosciences Inc. with AIEarnings Recap Report & Weekly High Conviction Ideas - Newser
Can Avidity Biosciences Inc. outperform under higher oil pricesJuly 2025 News Drivers & Expert Approved Trade Ideas - khodrobank.com
How to use a screener to detect Avidity Biosciences Inc. breakouts2025 Bull vs Bear & High Return Trade Opportunity Guides - Newser
Analyzing recovery setups for Avidity Biosciences Inc. investorsPortfolio Value Summary & Stepwise Trade Execution Plans - Newser
Published on: 2025-09-02 00:27:58 - khodrobank.com
Is Avidity Biosciences Inc. a potential multi baggerJuly 2025 EndofMonth & Expert Curated Trade Setup Alerts - khodrobank.com
Is Avidity Biosciences Inc. stock a top performer YTD2025 Price Momentum & AI Powered Trade Plan Recommendations - khodrobank.com
RNA Stock Price and Chart — NASDAQ:RNA - TradingView
What moving averages say about Avidity Biosciences Inc.July 2025 Trade Ideas & Free Risk Controlled Daily Trade Plans - Newser
Does Avidity Biosciences Inc. show high probability of reboundWeekly Trend Summary & Safe Entry Point Alerts - Newser
Published on: 2025-08-31 20:59:49 - Newser
Risk vs reward if holding onto Avidity Biosciences Inc.Quarterly Profit Report & Expert Approved Momentum Ideas - Newser
Is Avidity Biosciences Inc.’s ROE strong enough2025 Key Lessons & Expert-Curated Trade Recommendations - sundaytimes.kr
Can Avidity Biosciences Inc. recover in the next quarterPortfolio Update Summary & Real-Time Volume Analysis - Newser
Is This a Bottoming Phase for Avidity Biosciences Inc. getLinesFromResByArray error: size == 0 - 더경남뉴스
How to monitor Avidity Biosciences Inc. with trend dashboardsGlobal Markets & Daily Chart Pattern Signal Reports - Newser
Sentiment analysis tools applied to Avidity Biosciences Inc.Earnings Risk Report & Real-Time Volume Spike Alerts - Newser
Should you wait for a breakout in Avidity Biosciences Inc.July 2025 Action & Weekly Top Stock Performers List - Newser
RNA Stock Moves More Than 30% in a Week: What's Driving This Rally? - MSN
Recovery Setup Building in Avidity Biosciences Inc. Experts Say getLinesFromResByArray error: size == 0 - kangso.co.kr
Avidity Biosciences Inc Azioni (RNA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Avidity Biosciences Inc Azioni (RNA) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Gallagher Kathleen P. | Chief Program Officer |
Sep 02 '25 |
Sale |
47.42 |
188 |
8,915 |
50,204 |
| Boyce Sarah | President and CEO |
Aug 28 '25 |
Option Exercise |
1.24 |
25,000 |
31,000 |
330,871 |
| Boyce Sarah | President and CEO |
Aug 28 '25 |
Sale |
49.39 |
25,000 |
1,234,700 |
305,871 |
1.75%
1.11%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):